Fundamental study on development of intestinal epithelial cell regeneration mechanism based on myofibroblast regulation

• Project/Area Number: 15K08968
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Shiga University of Medical Science
• Principal Investigator: BAMBA Shigeki 滋賀医科大学, 医学部, 講師 (40422901)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 腸管上皮細胞 / 筋線維芽細胞 / 炎症性腸疾患 / Foxl1 / Schizophyllan / 腸管再生

Outline of Final Research Achievements

Myofibroblasts are known to play an important role in inflammatory bowel diseases. Schizophyllan (SPG) can be used as a transporter of DNA sequence into cytoplasm via Dectin-1 which is expressed on the surface of myofibroblasts. We have investigated the application of this drug delivery system focusing on Foxl1. Inhibition of Foxl1 using antisense-Foxl1/SPG complex ameliorates body weight loss and significant increase in length of the colon and crypts in dextran sodium sulfate (DSS) colitis model.